[Radiation-related CML].

N Kamada

Home/Archive/PubMed

PubMed · 11766334

[Radiation-related CML].

N Kamada

View original source ↗Export metadata ↓

Abstract

The clinical, cytogenetic and molecular-genetic findings of 55 patients with radiation related chronic myelocytic leukemia(CML) among the Hiroshima atomic bomb survivors were compared with 167 CML patients without a history of the radiation exposure. The retrospective analysis of the hematological data kept at the laboratory center where the survivors had been examined twice a year revealed a possible chronologic sequence in appearance of clinical and laboratory findings characteristic of CML. No particular differences were observed between the two groups in the incidence of Philadelphia chromosome and break points of the BCR gene, contrasting with those of radiation-related acute myelocytic leukemia which showed complex chromosome abnormalities without specific type of translocations, especially of 8;21 and 15;17, and a high incidence of genetic instability of the leukemic cells.

Explore related subjects

Genes, abl Humans Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Radiation-Induced Nuclear Warfare Philadelphia Chromosome Retrospective Studies English Abstract Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

N Kamada. 2001. [Radiation-related CML].. https://pubmed.ncbi.nlm.nih.gov/11766334/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Oncogenic mechanisms in myeloproliferative disorders.

Myeloproliferative disorders (MPDs) are clonal haematopoietic malignancies involving the abnormal proliferation of myeloid lineages. The World Health Organisation (WHO) classification of haematopoietic malignancies distinguishes MPDs from myelodysplastic/ myeloproliferative disorders and systemic mastocytosis. These malignancies frequently involve constitutive tyrosine kinase activity, resulting from either oncogenic fusion protein production or from point mutations. Chronic myelogenous leukaemia is the model used for studies of the consequences of such molecular defects. However, the heterogeneity of the clinical course of MPDs should be seen in a more rationale conceptual framework, including the many molecular events associated with these diseases. This review focuses on the various tyrosine kinase-related molecular mechanisms underlying both MPDs and rare diseases with myeloproliferative features. We pay particular attention to the newly identified JAK2 V617F mutation in polycythaemia vera, essential thrombocythaemia and idiopathic myelofibrosis and deal with disease heterogeneity and putative additional molecular mechanisms.

Genes, abl↗

PubMed2004

[Detection of minimal residual disease of chronic myeloid leukemia patients after allogeneic stem cell transplantation by combination of STR-PCR with RT-PCR].

In order to evaluate relapse predication ability of STR-PCR combining with qualitative RT-PCR for the bar/abl transcripts to the patient with chronic myeloid leukemia (CML) fulfilled allogeneic stem cell transplantation (allo-HSCT), 24 patients with CML after allo-HSCT were dynamically investigated for MRD, quantitative analysis of donor chimerism was performed by multiplex PCR amplification of STR markers and capillary electrophoresis with fluorescence detection, qualitative detection of bcr/abl transcripts was detected by nested RT-PCR. The results showed that persistent full donor chimerism (DC >/= 95%) was associated with an absence of MRD. All patients with stable MC (90% </= DC < 95%) and bcr/abl negative had a probability of long-term survival with molecular remission, however the result of bcr/abl positivity was not always associated with leukemia relapse, only the patient with decreasing values of donor chimerism as well as bcr/abl positive proved to be in a higher risk of relapse or graft failure. Decrease of donor chimerism in correlation with MRD positive was detected in 5 patients. Three out of five patients had been proved to have a molecular relapse, one out of five patients had developed to cytogenetic relapse and another patient experienced graft failure. It is concluded that the results of STR-PCR in the range of its sensitivity fully correspond with bcr/abl tests in patients. The combination of STR-PCR with RT-PCR will provide a highly sensitive and valuable tool for MRD detection in CML and can identify these high risk patients with molecular or cytogenetic relapse after allo-HSCT.

Genes, abl↗

PubMed2002

Bcr-Abl variants: biological and clinical aspects.

Bcr-Abl is an oncogene that arises from fusion of the Bcr gene with the c-Abl proto-oncogene. Three different Bcr-Abl variants can be formed, depending on the amount of Bcr gene included: p185, p210, and p230. The three variants are associated with distinct types of human leukemias. Examination of the signaling pathways differentially regulated by the Bcr-Abl proteins will help us gain better insight into Bcr-Abl mediated leukemogenesis.

Genes, abl↗